| Deep Vein Thrombosis
Savaysa vs Eliquis
Side-by-side clinical, coverage, and cost comparison for deep vein thrombosis.Deep comparison between: Savaysa vs Eliquis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEliquis has a higher rate of injection site reactions vs Savaysa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eliquis but not Savaysa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Savaysa
Eliquis
At A Glance
Oral
Daily
Factor Xa inhibitor
Oral
Twice daily
Factor Xa inhibitor
Indications
- Nonvalvular atrial fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Venous Thromboembolism
Dosing
Nonvalvular atrial fibrillation 60 mg orally once daily in patients with CrCL >50 to <=95 mL/min; reduce to 30 mg once daily for CrCL 15-50 mL/min; do not use in patients with CrCL >95 mL/min.
Deep Vein Thrombosis, Pulmonary Embolism 60 mg orally once daily following 5-10 days of initial parenteral anticoagulant therapy; reduce to 30 mg once daily for CrCL 15-50 mL/min, body weight <=60 kg, or concomitant use of certain P-gp inhibitors.
Atrial Fibrillation 5 mg orally twice daily; 2.5 mg twice daily in patients with at least 2 of the following: age >=80 years, body weight <=60 kg, or serum creatinine >=1.5 mg/dL.
Deep Vein Thrombosis (prophylaxis, hip or knee replacement) 2.5 mg orally twice daily initiated 12-24 hours post-surgery; 35 days for hip replacement, 12 days for knee replacement.
Deep Vein Thrombosis, Pulmonary Embolism (treatment) 10 mg orally twice daily for 7 days, then 5 mg twice daily.
Deep Vein Thrombosis, Pulmonary Embolism (recurrence reduction) 2.5 mg orally twice daily after at least 6 months of treatment for DVT or PE.
Venous Thromboembolism (pediatric) Weight-based dosing orally twice daily following at least 5 days of initial anticoagulant treatment; doses range from 0.3 mg to 10 mg twice daily based on weight tier.
Contraindications
- Active pathological bleeding
- Active pathological bleeding
- Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)
Adverse Reactions
Most common (>=1%) Rash, abnormal liver function tests, anemia
Serious Intracranial hemorrhage, gastrointestinal bleeding, fatal bleeding
Postmarketing Thrombocytopenia, abdominal pain, angioedema, hypersensitivity, dizziness, headache, anticoagulant-related nephropathy, urticaria
Most common (>=1%) Epistaxis, contusion, hematuria, menorrhagia, hematoma, hemoptysis, rectal hemorrhage, gingival bleeding, nausea, anemia.
Serious Major bleeding including intracranial hemorrhage, gastrointestinal bleeding, and fatal bleeding.
Pharmacology
Edoxaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; inhibition of FXa in the coagulation cascade reduces thrombin generation and thrombus formation.
Apixaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; by inhibiting free and clot-bound FXa and prothrombinase activity, it decreases thrombin generation and thrombus development without directly affecting platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Savaysa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (9/12)
Eliquis
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Savaysa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (4/8)
Eliquis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Savaysa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Eliquis
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Savaysa.
No savings programs available for Eliquis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SavaysaView full Savaysa profile
EliquisView full Eliquis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.